The Latest Breaking News from FATE

"March of Outrage" in Argentina: What Are Citizens Demanding?

Tens of thousands marched against Milei in Buenos Aires. What the 'Marcha de la Bronca' manifesto demands from unions, and what the numbers dispute.

Latin Times · Sep 21

Dystopian New Dating Method Is Taking Over California Colleges As Dominates ‘Primitive’ Tinder

Netizens are freaking out as Dating apps have started offering AI-powered solutions, poised to replace the habit of endlessly swiping until you find “the one.”

Bored Panda · Jul 15

No swiping involved: the AI dating apps promising to find your soulmate

Agentic AI apps first interview you and then give you limited matches selected for ‘similarity and reciprocity of personality’

The Guardian - UK · Feb 15

Jared Goff is the Lions nominee for the Walter Payton NFL Man of the Year award

The award honors off-field excellence and community service and is highly coveted by players

USA Today Sports Media Group · Dec 6, 2022

In fighting gun crime, Canada has an American problem

A Texas man bought dozens of guns from licensed dealers in the state before illegally reselling at least 16, U.S. officials say. Twelve were traced to crimes committed in America. The other four were traced to crimes in Canada.

Reuters · Jul 27, 2022

Recap: Fate Therapeutics Q1 Earnings

Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

StockNews.com · Apr 21, 2022

What 4 Analyst Ratings Have To Say About Fate Therapeutics

Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings:

Benzinga · Mar 4, 2022

Looking Into Fate Therapeutics's Return On Capital Employed

Benzinga Pro data, Fate Therapeutics (NASDAQ:FATE) reported Q4 sales of $17.07 million. Earnings fell to a loss of $68.62 million, resulting in a 58.45% decrease from last quarter.

Benzinga · Mar 2, 2022

Fate Therapeutics: Q4 Earnings Insights

Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Feb 28, 2022